Transthyretin Amyloidosis Treatment Market on Track for Strong Growth, Estimated to Grow at 8.3% CAGR Through 2029

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Transthyretin Amyloidosis Treatment Market Through 2025?
The market valuation for transthyretin amyloidosis treatments has experienced robust expansion across recent years, projecting an increase from its 2024 figure of $4.59 billion to $4.96 billion by 2025, signifying an 8.0% compound annual growth rate during this interval; this uptrend during the past period stems from several factors, including heightened recognition of the condition, progress in identifying the disease, the introduction and clearance of novel therapeutics, vigorous efforts from patient support groups, and cooperative research undertakings.

What's the Projected Size of the Global Transthyretin Amyloidosis Treatment Market by 2029?
Anticipated for robust expansion, the market for transthyretin amyloidosis treatments is projected to reach a valuation of $6.83 billion by the year 2029, exhibiting a compound annual growth rate (CAGR) of 8.3% over the coming period. This projected upward trajectory is fundamentally driven by several key factors: the broadening scope of therapeutic candidates in development, heightened efforts in genetic identification, worldwide campaigns aimed at raising awareness for this rare condition, the increasing utilization of customized medical strategies, and enhanced treatment availability for patients. Furthermore, significant shifts shaping this market during the forecast timeframe encompass the rise of synergistic treatment regimens, mutually beneficial alliances formed to advance pharmaceutical innovation, a dedicated emphasis on addressing manifestations within both the peripheral nervous system and the heart, the deployment of structured educational initiatives for patients, and the integration of practical, real-world data into established treatment protocols.

View the full report here:
https://www.thebusinessresearchcompany.com/report/transthyretin-amyloidosis-treatment-global-market-report

Top Growth Drivers in the Transthyretin Amyloidosis Treatment Industry: What's Accelerating the Market?
Anticipated escalation in funding directed toward research and development initiatives is poised to accelerate the expansion of the market for transthyretin amyloidosis therapies. This commitment to R&D encompasses the deployment of capital toward endeavors focused on furthering scientific understanding, pioneering fresh technologies, engineering novel products, and refining current methodologies. Greater financial support for research and development facilitates the identification and creation of cutting-edge therapeutic strategies for transthyretin amyloidosis, encompassing new pharmaceuticals, genetic interventions, and customized medical approaches, consequently furnishing patients with superior and more focused avenues for care. As an illustration, in December 2022, Alnylam Pharmaceuticals, an American biopharmaceutical firm involved in advancing Vutrisiran, a therapy for ATTR amyloidosis, significantly boosted its R&D expenditure to $883,015 that year, a notable rise from the $792,156 allocated in 2021, demonstrating an 11.49 percent increase; consequently, this augmentation in research investment is set to serve as a crucial catalyst for the progression of the transthyretin amyloidosis treatment market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13129&type=smp

What Trends Will Shape the Transthyretin Amyloidosis Treatment Market Through 2029 and Beyond?
The key players within the market for transthyretin amyloidosis therapies are concentrating their efforts on creating novel and targeted interventions, particularly orphan drugs, with the goal of improving results for patients and broadening the available therapeutic landscape. Eplontersen constitutes an orphan drug crafted exclusively for managing transthyretin amyloidosis, frequently benefiting from regulatory incentives that bolster its progression. To illustrate, in March of 2023, Ionis Pharmaceuticals, Inc., a biotechnology firm situated in Canada, secured approval from The Food and Drug Administration (FDA) for a new drug application concerning Eplontersen, an investigational orphan therapeutic aimed at treating familial transthyretin-mediated amyloidosis that causes advancing polyneuropathy. This pharmaceutical entity, Eplontersen, was engineered to diminish the production of the transthyretin (TTR) protein, thereby targeting both inherited and sporadic forms of ATTR amyloidosis (amyloid transthyretin amyloidosis), and it had previously been awarded orphan drug status by the FDA during 2022.

What Are the Main Segments in the Transthyretin Amyloidosis Treatment Market?
The transthyretin amyloidosis treatmentmarket covered in this report is segmented -

1) By Type: Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN); Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
2) By Drug: Tafamidis; Patisiran; Inotersen; Other Drugs
3) By Therapy: Targeted Therapy; Supportive Therapy; Pipeline Therapy
4) By Distribution Channel: Hospital Pharmacies; Specialty Pharmacies; Retail Pharmacies; Online Pharmacies

Subsegments:
1) By Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN): Early-Stage ATTR-PN; Advanced-Stage ATTR-PN
2) By Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM): Mild ATTR-CM; Moderate ATTR-CM; Severe ATTR-CM

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13129&type=smp

Which Top Companies are Driving Growth in the Transthyretin Amyloidosis Treatment Market?
Major companies operating in the transthyretin amyloidosis treatment market report are Pfizer Inc., Abbvie Inc., Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, GSK PLC, Novo Nordisk A/S, Merck & Co. Inc., Astellas Pharma Inc., Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics, Ionis Pharmaceuticals, Prothena Corporation PLC, BridgeBio Pharma Inc., Sorrento Therapeutics Inc., Intellia Therapeutics, Akcea Therapeutics Inc., Eidos Therapeutics Inc., Acrotech Biopharma Inc., Spectrum Pharmaceuticals Inc., Neurimmune AG, BELLUS Health Inc., Corino Therapeutics Inc., Celgene Corp, SOM Innovation Biotech S.A

Which Regions Will Dominate the Transthyretin Amyloidosis Treatment Market Through 2029?
North America was the largest region in the transthyretin amyloidosis treatment market in 2024. The regions covered in the transthyretin amyloidosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13129

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.